Cargando…

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade

Tyrosine phosphatase SHP2 is a promising drug target in cancer immunotherapy due to its bidirectional role in both tumor growth promotion and T-cell inactivation. Its allosteric inhibitor SHP099 is known to inhibit cancer cell growth both in vitro and in vivo. However, whether SHP099-mediated SHP2 i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Mingxia, Guo, Wenjie, Wu, Yuanyuan, Yang, Chenxi, Zhong, Liang, Deng, Guoliang, Zhu, Yuyu, Liu, Wen, Gu, Yanhong, Lu, Yin, Kong, Lingdong, Meng, Xiangbao, Xu, Qiang, Sun, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437555/ https://www.ncbi.nlm.nih.gov/pubmed/30972278 http://dx.doi.org/10.1016/j.apsb.2018.08.009

Ejemplares similares

T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice
por: Liu, Wen, et al.
Publicado: (2016)

Loss of hnRNP A1 in murine skeletal muscle exacerbates high-fat diet-induced onset of insulin resistance and hepatic steatosis
por: Zhao, Mingxia, et al.
Publicado: (2019)

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
por: Fang, Douglas D., et al.
Publicado: (2019)

Single-cell analyses reveal cannabidiol rewires tumor microenvironment via inhibiting alternative activation of macrophage and synergizes with anti-PD-1 in colon cancer
por: Sun, Xiaofan, et al.
Publicado: (2023)

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
por: Lu, Lei, et al.
Publicado: (2014)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
por: Liu, Peng, et al.
Publicado: (2022)

SHP2-mediated mitophagy boosted by lovastatin in neuronal cells alleviates parkinsonism in mice
por: Liu, Wen, et al.
Publicado: (2021)

Loss of SHP-2 activity in CD4(+) T cells promotes melanoma progression and metastasis
por: Zhang, Tao, et al.
Publicado: (2013)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation
por: Patsoukis, Nikolaos, et al.
Publicado: (2020)

Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis
por: Zhu, Yuyu, et al.
Publicado: (2021)

PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells
por: Liotti, Federica, et al.
Publicado: (2021)

Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade
por: Ocadlikova, Darina, et al.
Publicado: (2021)

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022)

SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
por: Christofides, Anthos, et al.
Publicado: (2022)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

CaCO(3) powder-mediated biomineralization of antigen nanosponges synergize with PD-1 blockade to potentiate anti-tumor immunity
por: Su, Runping, et al.
Publicado: (2023)

PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
por: Xu, Xiaozheng, et al.
Publicado: (2020)

A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
por: Tondini, Elena, et al.
Publicado: (2019)

Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis
por: Guan, Xin, et al.
Publicado: (2022)

Intravesical VAX014 Synergizes with PD-L1 Blockade to Enhance Local and Systemic Control of Bladder Cancer
por: Tsuji, Shingo, et al.
Publicado: (2022)

Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis
por: Gao, Jian, et al.
Publicado: (2019)

Synergism of Multicomponent Catalysis: One-Dimensional Pt-Rh-Pd Nanochain Catalysts for Efficient Methanol Oxidation
por: Jiang, Yang, et al.
Publicado: (2020)

Tyrosine phosphatase SHP2 negatively regulates NLRP3 inflammasome activation via ANT1-dependent mitochondrial homeostasis
por: Guo, Wenjie, et al.
Publicado: (2017)

Molecular mechanism of SHP2 activation by PD-1 stimulation
por: Marasco, M., et al.
Publicado: (2020)

Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
por: Wei, Huafeng, et al.
Publicado: (2013)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity
por: Zheng, Shuang, et al.
Publicado: (2023)

CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner
por: Zhang, Qian-Feng, et al.
Publicado: (2020)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

Immunogenic Cell Death Inducing Fluorinated Mitochondria‐Disrupting Helical Polypeptide Synergizes with PD‐L1 Immune Checkpoint Blockade
por: Jeong, Seong Dong, et al.
Publicado: (2021)

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity
por: El-Sayes, Nader, et al.
Publicado: (2022)

Glutathione Pulse Therapy: Promote Spatiotemporal Delivery of Reduction‐Sensitive Nanoparticles at the “Cellular Level” and Synergize PD‐1 Blockade Therapy
por: Dong, Songtao, et al.
Publicado: (2022)

SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms
por: Wang, Ye, et al.
Publicado: (2021)

Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors
por: Toral, Keller J., et al.
Publicado: (2021)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

Tyrosine phosphatase SHP2 exacerbates psoriasis‐like skin inflammation in mice via ERK5‐dependent NETosis
por: Ding, Yan, et al.
Publicado: (2022)

Preclinical to clinical translation of anti-PD-1 blockade
por: Hirsch, Heather, et al.
Publicado: (2015)

Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy
por: Jiang, Mingxia, et al.
Publicado: (2021)

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
por: Arce Vargas, Frederick, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v52401pi17mohcmlv5t8bltj5n